SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☑ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person*	2. Issuer Name **and** Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
Mahboob Vaseem	KESTRA MEDICAL TECHNOLOGIES, LTD. [KMTS]	☐ Director ☐ 10% Owner
(Last) (First) (Middle)	Foreign Trading Symbol	☑ Officer (give title below) ☐ Other (specify below)
3933 LAKE WASHINGTON BLVD NE, SUITE 200	3. Date of Earliest Transaction (Month/Day/Year)	Chief Financial Officer
(Street)	10/27/2026	
KIRKLAND WA 98033	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)
(City) (State) (Zip)		☑ Form filed by One Reporting Person ☐ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Shares	10/27/2026		M[1]		34,809	A	$17	95,418	D	
Common Shares	10/27/2026		S[1]		34,809	D	$30.0435[2]	60,609	D	
Common Shares	10/28/2026		M[1]		39,903	A	$17[2]	100,512	D	
Common Shares	10/28/2026		S[1]		39,903	D	$30.4815[3]	60,609	D	
Common Shares	10/29/2026		M[1]		4,788	A	$17[2]	65,397	D	
Common Shares	10/29/2026		S[1]		4,788	D	$30.5979[4]	60,609	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Options	$17	10/27/2026		M			34,809	(5)	03/06/2035	Common Stock	34,809	$0	124,191	D	
Options	$17	10/28/2026		M			39,903	(6)	03/06/2035	Common Stock	39,903	$0	84,288	D	
Options	$17	10/29/2026		M			4,788	(7)	03/06/2035	Common Stock	4,788	$0	79,500	D	

Explanation of Responses:

1. This reported transaction is a scheduled exercise and sale pursuant to a Rule 10b5-1 trading plan adopted on November 5, 2025.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $30.0000 to $30.4300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $30.0100 to $30.9800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $30.3500 to $31.0400. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

5. Includes 91,066 fully vested options as of the transaction date, with the remaining 33,125 options vesting in equal monthly installments through March 6, 2027.

6. Includes 51,163 fully vested options as of the transaction date, with the remaining 33,125 options vesting in equal monthly installments through March 6, 2027.

7. Includes 46,375 fully vested options as of the filing date, with the remaining 33,125 options vesting in equal monthly installments through March 6, 2027.

/s/ Traci S. Umberger as attorney-in-fact for Vaseem Mahboob — 10/29/2026

** Signature of Reporting Person — Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.